Literature DB >> 18316630

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.

Maria Mamani-Matsuda1, Antonio Cosma, Sandra Weller, Ahmad Faili, Caroline Staib, Loïc Garçon, Olivier Hermine, Odile Beyne-Rauzy, Claire Fieschi, Jacques-Olivier Pers, Nina Arakelyan, Bruno Varet, Alain Sauvanet, Anne Berger, François Paye, Jean-Marie Andrieu, Marc Michel, Bertrand Godeau, Pierre Buffet, Claude-Agnès Reynaud, Jean-Claude Weill.   

Abstract

The fact that you can vaccinate a child at 5 years of age and find lymphoid B cells and antibodies specific for this vaccination 70 years later remains an immunologic enigma. It has never been determined how these long-lived memory B cells are maintained and whether they are protected by storage in a special niche. We report that, whereas blood and spleen compartments present similar frequencies of IgG(+) cells, antismallpox memory B cells are specifically enriched in the spleen where they account for 0.24% of all IgG(+) cells (ie, 10-20 million cells) more than 30 years after vaccination. They represent, in contrast, only 0.07% of circulating IgG(+) B cells in blood (ie, 50-100,000 cells). An analysis of patients either splenectomized or rituximab-treated confirmed that the spleen is a major reservoir for long-lived memory B cells. No significant correlation was observed between the abundance of these cells in blood and serum titers of antivaccinia virus antibodies in this study, including in the contrasted cases of B cell-depleting treatments. Altogether, these data provide evidence that in humans, the two arms of B-cell memory--long-lived memory B cells and plasma cells--have specific anatomic distributions--spleen and bone marrow--and homeostatic regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316630     DOI: 10.1182/blood-2007-11-123844

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Authors:  Kai W Bekar; Teresa Owen; Robert Dunn; Travis Ichikawa; Wensheng Wang; Roger Wang; Jennifer Barnard; Sean Brady; Sarah Nevarez; Bruce I Goldman; Marilyn Kehry; Jennifer H Anolik
Journal:  Arthritis Rheum       Date:  2010-08

2.  Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab.

Authors:  Alice Cho; Bridget Bradley; Robert Kauffman; Lalita Priyamvada; Yevgeniy Kovalenkov; Ron Feldman; Jens Wrammert
Journal:  JCI Insight       Date:  2017-06-15

3.  Multiple layers of B cell memory with different effector functions.

Authors:  Ismail Dogan; Barbara Bertocci; Valérie Vilmont; Frédéric Delbos; Jérome Mégret; Sébastien Storck; Claude-Agnès Reynaud; Jean-Claude Weill
Journal:  Nat Immunol       Date:  2009-10-25       Impact factor: 25.606

Review 4.  The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy.

Authors:  Malika Hale; David J Rawlings; Shaun W Jackson
Journal:  Curr Opin Immunol       Date:  2018-11-01       Impact factor: 7.486

5.  CD19-positive antibody-secreting cells provide immune memory.

Authors:  C J Groves; J Carrell; R Grady; B Rajan; C A Morehouse; R Halpin; J Wang; J Wu; Y Shrestha; R Rayanki; R Kolbeck; Y Wang; R Herbst
Journal:  Blood Adv       Date:  2018-11-27

6.  Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity.

Authors:  Michael A Maurer; Goran Rakocevic; Carol S Leung; Isaak Quast; Martin Lukačišin; Norbert Goebels; Christian Münz; Hedda Wardemann; Marinos Dalakas; Jan D Lünemann
Journal:  J Clin Invest       Date:  2012-03-19       Impact factor: 14.808

7.  Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

Authors:  Davide Bedognetti; Filippo Ansaldi; Elisa Zanardi; Paolo Durando; Mario Roberto Sertoli; Carlotta Massucco; Enrico Balleari; Omar Racchi; Gabriele Zoppoli; Andrea Orsi; Cristiano Alicino; Giancarlo Icardi; Francesco M Marincola; Simonetta Zupo; Manlio Ferrarini; Andrea De Maria
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

8.  Human Extrafollicular CD4+ Th Cells Help Memory B Cells Produce Igs.

Authors:  Sang Taek Kim; Jin-Young Choi; Begona Lainez; Vincent P Schulz; David E Karas; Eric D Baum; Jennifer Setlur; Patrick G Gallagher; Joe Craft
Journal:  J Immunol       Date:  2018-07-20       Impact factor: 5.422

9.  The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.

Authors:  Peter D Crompton; Marko Mircetic; Greta Weiss; Amy Baughman; Chiung-Yu Huang; David J Topham; John J Treanor; Iñaki Sanz; F Eun-Hyung Lee; Anna P Durbin; Kazutoyo Miura; David L Narum; Ruth D Ellis; Elissa Malkin; Gregory E D Mullen; Louis H Miller; Laura B Martin; Susan K Pierce
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.

Authors:  Matthew P Bernard; Simona Bancos; Timothy J Chapman; Elizabeth P Ryan; John J Treanor; Robert C Rose; David J Topham; Richard P Phipps
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.